Table 1. Summary of demographic, clinical features, and laboratory findings of the patients.

Characteristics	Values
Age, yr	48.9 ± 9.1 (27–76)
Sex (male:female)	43:52
Duration of clevudine therapy before symptom onset, mon	14.2 ± 3.9 (5–24)
Time to nadir of weakness in our seven cases, mon	8.6 ± 7.5 (3–24)
Distribution of weakness, No. of patients
Bulbar or neck	13 (13.7)
Arm	69 (72.6)
Proximal arm/distal arm	66/50
Leg	94 (98.9)
Proximal leg/distal leg	86/57
Grade of weakness, MRC grade
Proximal/distal, arm	4.5 ± 0.4/4.8 ± 0.4
Proximal/distal, leg	3.7 ± 0.4/4.3 ± 0.5
Myalgia, No. of patients	12 (12.6)
Recovery from discontinuation of clevudine, wk	11.8 ± 5.8 (2–36)
Elevated CK, No. of patients	93 (97.9)
Elevated liver enzymes (AST or ALT), No. of patients	85 (89.5)

Values are presented as mean ± standard deviation (range) or number (%).

MRC = Medical Research Council, CK = creatine kinase, AST = aspartate aminotransferase, ALT = alanine aminotransferase.